Postoperative Ocular Inflammation
📧 Sign up to get email alerts when something new happens for Postoperative Ocular Inflammation.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-12-13FDA Approved: DIFLUPREDNATE — Original Application (Caplin Steriles Limited)
The FDA approved Caplin Steriles Limited's original application for difluprednate, a generic ophthalmic corticosteroid, for treating ocular …
-
FDA approval · 2024-07-10FDA Approved: LOTEPREDNOL ETABONATE — Original Application (Padagis US LLC)
FDA approves Padagis US LLC Loteprednol etabonate ophthalmic suspension under an original ANDA application.
-
FDA approval · 2024-04-24FDA Approved: LOTEPREDNOL ETABONATE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' original application for Loteprednol etabonate, a generic ophthalmic corticosteroid for inflammatory eye…
-
CLINICAL_TRIALS trial_result · 2023-10-18Clinical Trial Update: Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects [Phase 2]
Phase 2 study evaluating SURF-201 eye drop in cataract surgery patients to assess efficacy in reducing post-surgical ocular inflammation and…
-
FDA approval · 2023-04-12FDA Approved: LOTEPREDNOL ETABONATE — Original Application (ARMAS PHARMACEUTICALS INC.)
FDA approved Loteprednol etabonate ophthalmic suspension from Armas Pharmaceuticals Inc. under an Original Application for use in ocular inf…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-11-16FDA Approved: DIFLUPREDNATE OPHTHALMIC EMULSION — Original Application (Dr. Reddy's Laboratories Inc.)
The FDA approved Dr. Reddy's Difluprednate Ophthalmic Emulsion (0.05%) as an original application, providing a generic option for treating o…
-
FDA approval · 2021-12-10FDA Approved: MAXIDEX — Supplemental Application (Harrow Eye, LLC)
FDA approved a supplemental application for MAXIDEX (dexamethasone) by Harrow Eye, LLC.
-
FDA approval · 2021-11-17FDA Approved: DIFLUPREDNATE — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved an original application for difluprednate ophthalmic (generic) manufactured by Amneal Pharmaceuticals NY LLC.
-
CLINICAL_TRIALS trial_result · 2020-12-22Clinical Trial Update: Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation [Phase 3]
Phase 3 trial assessing KPI-121 for safety and efficacy in postsurgical ocular inflammation/infection completed with posted results.
-
FDA approval · 2020-06-04FDA Approved: DEXYCU — Supplemental Application (EyePoint Pharmaceuticals US, Inc)
FDA approved a supplemental application for DEXYCU (dexamethasone intraocular suspension) to expand its label for postoperative ocular infla…
-
FDA approval · 2020-04-24FDA Approved: INVELTYS — Supplemental Application (ALCON LABORATORIES, INC.)
The FDA approved a supplemental application for INVELTYS (loteprednol etabonate) from Alcon Laboratories, Inc. The action likely involves la…
-
CLINICAL_TRIALS trial_result · 2019-04-17Clinical Trial Update: Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain [Phase 3]
Phase 3 trial update on KPI-121 for post-surgical ocular inflammation and pain shows safety and efficacy results.
-
FDA approval · 2018-08-22FDA Approved: INVELTYS — Original Application (ALCON LABORATORIES, INC.)
FDA approved INVELTYS (loteprednol etabonate) ophthalmic suspension 1% from Alcon Laboratories as an original application for the treatment …
-
FDA approval · 2018-06-06FDA Approved: PRED MILD — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for PRED MILD (prednisolone acetate) by Allergan, Inc., adding a supplemental approval for this opht…
-
FDA approval · 2018-06-06FDA Approved: PRED FORTE — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for PRED FORTE (prednisolone acetate ophthalmic suspension) submitted by Allergan, Inc.
-
FDA approval · 2016-08-05FDA Approved: MAXIDEX — Supplemental Application (Harrow Eye, LLC)
The FDA approved a supplemental application for MAXIDEX (dexamethasone) from Harrow Eye, LLC, authorizing changes to the drug's labeling as …
-
CLINICAL_TRIALS trial_result · 2016-07-13Clinical Trial Update: Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers [Phase 1, Phase 2]
A phase 1/2 trial comparing dosing regimens of ISV-303 (bromfenac in DuraSite) to Xibrom and vehicle in ocular inflammation following catara…
-
FDA approval · 2016-03-10FDA Approved: MAXIDEX — Supplemental Application (Harrow Eye, LLC)
FDA approved a supplemental application for MAXIDEX (dexamethasone) from Harrow Eye, LLC.
-
FDA approval · 2015-12-02FDA Approved: BROMFENAC OPHTHALMIC SOLUTION — Supplemental Application (Bausch & Lomb Americas Inc.)
FDA approved a supplemental application for Bromfenac Ophthalmic Solution by Bausch & Lomb Americas, updating labeling to reflect postoperat…
-
FDA approval · 2013-10-09FDA Approved: LOTEPREDNOL ETABONATE — Supplemental Application (Bausch & Lomb Americas Inc.)
FDA approved a supplemental application for Loteprednol etabonate (Lotemax) by Bausch & Lomb Americas Inc., approving changes to the product…
-
FDA approval · 2012-11-27FDA Approved: DIFLUPREDNATE OPHTHALMIC — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for difluprednate ophthalmic from Sandoz Inc, authorizing changes to its labeling following submissi…
-
CLINICAL_TRIALS research · 2012-05-22Clinical Trial Update: Efficacy of Moxifloxacin/Prednisolone in Prevention of Post Surgery Inflammation [Phase 3]
A Phase 3 clinical trial evaluating a moxifloxacin/prednisolone ophthalmic formulation to prevent postoperative ocular inflammation; current…
-
FDA approval · 2008-06-23FDA Approved: DIFLUPREDNATE OPHTHALMIC — Original Application (Sandoz Inc)
FDA approved the original application for difluprednate ophthalmic from Sandoz, a corticosteroid eye drop for ocular inflammation associated…